PETALING JAYA: Pharmaniaga Bhd
’s net profit for its first quarter ended March 31, 2026 rose to RM31.47mil from RM29.58mil in the previous corresponding period, while revenue grew to RM1.18bil from RM1.06bil a year earlier.
In a filing with Bursa Malaysia, the pharmaceutical company said revenue growth was primarily attributable to the higher volume order from government hospitals for stock keeping units under the Approved Products Purchase List during the quarter.
“The group realised interest savings of RM7.2mil following the partial repayment of borrowings, supported by effective inventory management, which contributed to a profit before zakat and taxation of RM46.4mil.”
Pharmaniaga said it remains committed to cost optimisation initiatives and enhancing operational efficiency to strengthen profit margins and drive sustainable profitability.
“Following the successful upliftment from Practice Note 17 or PN17 classification on March 17, 2026, Pharmaniaga has returned to a stable financial position and is focused on strengthening its market standing. In line with this, the group has proposed a share consolidation of every five existing ordinary shares into one consolidated share.”
Pharmaniaga said the exercise is expected to be completed in early June 2026 and is anticipated to enhance share price stability and improve overall market perception.
“The biopharmaceutical segment continues to gain traction as a key growth pillar for the group.
“The anticipated commencement of human insulin supply in mid-2026 represents a significant milestone and is expected to contribute positively to future performance.”
Within the pharmaceutical segment, Pharmaniaga said it has strengthened its product offerings in the cardiovascular and urology segments with the launch of Apixaban and Dutasteride in the first quarter of 2026.
“The planned introduction of the Gemigliptin product range, including its combination variants, in the second quarter of 2026 is expected to further enhance the group’s anti-diabetic and metabolic portfolio,” it added.
